NCT01976390View on ClinicalTrials.gov

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

NACompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

July 11, 2018

Study Completion Date

August 31, 2019

Conditions

Renal Failure

Interventions

DRUG

Everolimus

0.75mg twice a day, Orally, starting on day of transplant

DRUG

Sirolimus

5mg, Orally, starting on day of transplant; decreasing to 3mg

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Ohio State University

OTHER